Sign in Subscribe
Cancer

Efficacy of Combination Therapy for Gallbladder Cancer Enhances Tumor-Specific Suicide Gene Therapy

Strategic Insights

— 1 min read

Researchers from the University of Tsukuba have made a significant breakthrough in the treatment of gallbladder cancer, showcasing the potential of a combination therapy approach. The study, published in Cancer Gene Therapy, demonstrates that the efficacy of a replication-deficient adenovirus-based herpes simplex virus thymidine kinase (HSVtk)/ganciclovir (GCV) therapy can be augmented by the addition of a replicating adenovirus, AxdAdB-3, directed by the carcinoembryonic antigen (CEA) promoter. This combination therapy showed improved efficacy in treating gallbladder cancer xenografts in severe combined immunodeficiency disease mice, while minimizing toxicity to normal cells.

Key Takeaways:

  • The study demonstrated that the addition of AxdAdB-3 (1 multiplicity of infection, MOI) significantly enhanced the cytopathic effects of AxCEAprTK (10 MOI)/GCV on gallbladder cancer cells.
  • The augmented effect was attributed to the replication of AxCEAprTK and the enhanced CEA promoter activity, which was presumably transactivated by E1A.
  • The combination therapy showed specificity for tumor cells, as normal cells were not affected by the treatment.
  • Low-dose AxdAdB-3 (2 x 10^7 PFU) plus AxCEAprTK (2 x 10^8 PFU)/GCV significantly suppressed the growth of gallbladder cancer xenografts compared to either AxdAdB-3 or AxCEAprTK alone.
  • The study highlights the potential use of this combination therapy for treating gallbladder cancer and other CEA-producing malignancies.

Statistics:

  • The study used several gallbladder cancer cell lines and normal cells in their experiments.
  • The addition of 1 MOI of AxdAdB-3 significantly enhanced the cytopathic effects of AxCEAprTK (10 MOI)/GCV on gallbladder cancer cells.
  • The combination therapy using AxdAdB-3 (2 x 10^7 PFU) and AxCEAprTK (2 x 10^8 PFU)/GCV suppressed the growth of gallbladder cancer xenografts by 50% compared to the control group.

Sources:

  • K. Fukuda et al. (2009). E1A, E1B double-restricted replicative adenovirus at low dose greatly augments tumor-specific suicide gene therapy for gallbladder cancer. Cancer Gene Therapy, 16(2), 126-136.
  • University of Tsukuba, Graduate School Comprehensive Human Science, Division Gastroenterology, 1-1-1 Tennoudai, Tsukuba, Ibaraki 3058575, Japan.
  • Nature Publishing Group, Macmillan Building, 4 Crinan St., London N1 9XW, England.
  • NewsRx.com. (2009). Cancer Gene Therapy Week editors from staff and other reports.

Read more